Related Experiment Video

Updated: Jul 7, 2026

Bacterial Delivery of RNAi Effectors: Transkingdom RNAi
07:56

Bacterial Delivery of RNAi Effectors: Transkingdom RNAi

Published on: August 18, 2010

Targeted delivery of small interfering RNA: approaching effective cancer therapies

Kathleen F Pirollo1, Esther H Chang

  • 1Department of Oncology, Georgetown University Medical Center, Washington, District of Columbia 20057-1469, USA.

Cancer Research
|March 5, 2008
PubMed

Insights

Developing an immunoliposome nanocomplex for systemic delivery can overcome limitations of small interfering RNA (siRNA) cancer therapy. This approach enhances tumor targeting and transfection efficiency for effective treatment.

Area of Science:

  • Oncology
  • Nanotechnology
  • Molecular Biology

Background:

  • Effective cancer therapeutics require tumor-specific delivery, cellular uptake, and pathway targeting.
  • Small interfering RNA (siRNA) faces challenges like poor delivery, low transfection, and instability, hindering clinical use.

Purpose of the Study:

  • To develop a novel systemically administered, tumor-specific immunoliposome nanocomplex.
  • To overcome the limitations of current siRNA-based cancer therapies.

Main Methods:

  • Design of a tumor-specific immunoliposome nanocomplex for systemic administration.
  • Evaluation of the nanocomplex for enhanced tumor targeting and transfection efficiency.

Main Results:

  • The immunoliposome nanocomplex demonstrates potential for overcoming key siRNA delivery barriers.
  • High transfection efficiency and targeted delivery are key features of the developed system.

Conclusions:

  • Systemic delivery of immunoliposome nanocomplexes offers a promising strategy for siRNA cancer therapy.
  • This approach could enable the clinical translation of siRNA as an effective anticancer modality.

More Related Videos

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy12:03

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy

Published on: September 5, 2016

Related Concept Videos

Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...